Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neurocrine Biosciences (NBIX) Research & Development (2016 - 2025)

Neurocrine Biosciences' Research & Development history spans 16 years, with the latest figure at $258.2 million for Q4 2025.

  • For Q4 2025, Research & Development rose 39.12% year-over-year to $258.2 million; the TTM value through Dec 2025 reached $530.7 million, up 36.57%, while the annual FY2025 figure was $1.0 billion, 38.93% up from the prior year.
  • Research & Development reached $258.2 million in Q4 2025 per NBIX's latest filing, up from $250.0 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $258.2 million in Q4 2025 to a low of $3.0 million in Q2 2024.
  • Average Research & Development over 5 years is $99.4 million, with a median of $97.6 million recorded in 2021.
  • Peak YoY movement for Research & Development: soared 1894.44% in 2022, then crashed 97.94% in 2024.
  • A 5-year view of Research & Development shows it stood at $87.4 million in 2021, then skyrocketed by 35.01% to $118.0 million in 2022, then grew by 16.53% to $137.5 million in 2023, then surged by 34.98% to $185.6 million in 2024, then surged by 39.12% to $258.2 million in 2025.
  • Per Business Quant, the three most recent readings for NBIX's Research & Development are $258.2 million (Q4 2025), $250.0 million (Q3 2025), and $15.0 million (Q2 2025).